VJHemOnc is committed to improving our service to you

IMW 2019 | Bortezomib and lenalidomide as first-line treatment for older patients with myeloma

VJHemOnc is committed to improving our service to you

Peter Barth

Peter Barth, MD, of Brown University, Providence, RI, discusses the benefit found in triplet induction therapy compared to that of various double induction therapies in elderly multiple myeloma patients in a retrospective study. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter